VSIQQ® (Brolucizumab) – A Requirement to Discontinue Treatment with Vsiqq® in Patients who Develop Retinal Vasculitis and/or Retinal Vascular Occlusion, Typically in the Presence of Intraocular Inflammation

Novartis, as directed by the South African Health Products Regulatory Authority (SAHPRA), would like to inform you about the requirement to discontinue treatment with Vsiqq® in patients who develop retinal vasculitis and/or retinal vascular occlusion. Retinal vasculitis and retinal vascular occlusion are immune-mediated events, which...

The following holders of certificates of registration (HCRs), Aspen Pharmacare, GlaxoSmithKline (Pty) Ltd and Glenmark Pharmaceuticals South Africa (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), wish to draw your attention to the following important safety information associated with topical...

This guideline document determines basic requirements and recommendations for radiation protection and safety in dental radiography applications....

X-Ray equipment used in industrial radiography is subject to regulatory control in terms of Article 3(1) of the Hazardous Substances Act, 1973 (Act 15 of 1973), as amended. The body responsible for administering this legislation is SAHPRA: Radiation Control. This code of practice has been...

This document has been prepared to serve as a guideline in monitoring Radiation workers in a Theatre. It represents South African Health Products Regulatory Authority’s (SAHPRA’s) current thinking on the safety, quality and efficacy of medicines. It is not intended as an exclusive approach. SAHPRA...

This guideline stipulates the regulatory requirements for installations of fixed diagnostic X-ray units. Every medical diagnostic X-ray must meet the design safety specifications outlined in this document. The manufacturer / vendor must obtain a license to install from South African Health Products Regulatory Authority (SAHPRA)...